All In MedTech

Device Trial Radar · NCT05414617

Safety of Use of Pandora for Patients Suffering From Gonarthrosis

Prospective, Multicenter, Open Study Evaluating the Short-term Safety of Use of Pandora Administered in the Form of 1 Intra-articular Injection of Happyone or 3 Intra-articular Injections of Happysoft in Patients Suffering From Gonarthrosis

Last checked: Nov 20, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Jun 8, 2022

Primary completion

Jan 18, 2023

Study completion Jun 14, 2023

Sponsor

Lead sponsor
LabrhaNot on our public-company list
Sponsor type
Industry
Collaborators
Statitec
First posted
Jun 10, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 35 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The knee osteoarthritis is a frequent degenerative condition that mainly affects subjects over 60, population often weakened by numerous comorbidities and concomitant treatments, justifying the development of new therapies. The viscosupplementation is a symptomatic treatment for knee osteoarthritis ; the objective of this intra-articular injection of hyaluronic acid is to reduce knee pain and improve mobility. In practice, there are two protocols to administer viscosupplementation : in a single injection or in three injections performed weekly. The present clinical investigation has the objective to evaluate the safety of use of Pandora in a single injection or in three injections performed weekly.

Conditions

  • Knee Osteoarthritis

Interventions

  • Intra-articular single injectionDevice

    Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment. The injection will be performed at Day 1.

  • Intra-articular three injectionsDevice

    Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment. The injections will be performed at Days 1, 8 and 15.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse event attributable to the investigational Medical Device during the week following each injection.Time frame: 1 month

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hôpital Nord Franche-Comté, HNFC

    Belfort, France

  • Groupe Hospitalier de la Région Mulhouse Sud-Alsace, GHRMSA

    Mulhouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.